Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Experimental group:Conventional treatent and Ulinastatin
Control group:Conventional treatent
Sponsors
Shanghai Changzheng Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years; 2. In accordance with NCP criteria for severe and critical illness. Combined with the following epidemiological history, clinical manifestations, and pathogenic examinations to make a comprehensive judgment; 3. Will not participate in other drug clinical trials since the first day of Ulinastatin Injection admission; 4. Will sign written informed consent. Adolescents or patients who cannot sign informed consent must obtain informed consent from the guardian.
Exclusion criteria
Exclusion criteria: 1. With contraindications of Ulinastatin Injection; 2. Pregnant or lactating women; 3. Patients taking other urinary trypsin inhibitors; 4. Not suitable to participate in the clinical trial by investigator's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood gas;SOFA score; | — |
Secondary
| Measure | Time frame |
|---|---|
| 28 natural survival rate;TTCI (Time to Clinical Improvement);Days in hospital;Duration of non-invasive / invasive ventilation;Proportion of severe to light;Infection related data;Frequency of serious adverse events; | — |
Countries
China
Contacts
Public ContactZhaofen Lin,Wansheng Chen,Weifen Xie
Shanghai Changzheng Hospital
Outcome results
None listed